Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05345444 · ClinicalTrials.gov registry record · NA

Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE)

A NA study of Prostate Cancer, sponsored by Weill Medical College of Cornell University.

Active
Registry status
NA
Development phase
48
Enrollment target
1
Study location

NCT05345444 is a NA study of Prostate Cancer that is active but no longer recruiting, run by Weill Medical College of Cornell University. The registered enrollment target is 48 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05345444, a NA study of Prostate Cancer, is active but no longer recruiting, sponsored by Weill Medical College of Cornell University.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
48 participants
Enrollment target
1
Study location

Study Summary

This is a single-site trial for 42 subjects with intermediate risk prostate cancer who undergo Irreversible Electroporation (IRE) followed by Magnetic Resonance guided Radiotherapy MRgRT. The investigators hypothesize that the combined therapy will feasible and be safe to perform with low morbidity. Ultimately, RTIRE may provide optimal treatment for intermediate risk prostate cancer patients.

Conditions Studied

Prostate Cancer

Interventions

  • DEVICE IRE & MRgRT

Study Locations (1)

New York

  • Weill Cornell Medicine - New York

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2022-05-26
Est. Completion 2027-04
Phase NA

Sponsor

Weill Medical College of Cornell University

701 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05345444

The ClinicalTrials.gov registry entry for NCT05345444 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (92% lower). The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which IRE & MRgRT is the first listed.

NCT05345444 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT05345444 about?

NCT05345444 is a clinical study titled "Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE)". This is a single-site trial for 42 subjects with intermediate risk prostate cancer who undergo Irreversible Electroporation (IRE) followed by Magnetic Resonance guided Radiotherapy MRgRT. The investigators hypothesize that the combined therapy will feasible and be safe to perform with low morbidity....

What is the current status of trial NCT05345444?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 48 participants. The study started on 2022-05-26. Estimated completion is 2027-04.

What conditions does trial NCT05345444 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT05345444?

The interventions under investigation include: IRE & MRgRT (DEVICE).

Who is sponsoring clinical trial NCT05345444?

This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05345444 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.